TABLE 1.

Prospective studies on HHV-6 reactivation after BMT

Detection methodaSamplebNo. of patientsIncidence of active HHV-6 infection (%)Observed diseasedHHV-6 variantReference
PCRPBMC, BALF4146Vascular endothelial damage, GVHDNot determined389
PCRPBMC, plasma9242.5Myelosuppression, fever, delayed platelet and neutrophil engraftmentNot determined177
PCRPBL2260Delayed platelet engraftmentB266
PCRPBL, plasma6128Fever, engraftment failureB62
PCRPBMC37Not givenDelayed platelet and granulocyte engraftmentB421
PCRPBL, oral lavage fluid, urine5760Acute GVHD90% B, 10% A428
PCR, IHCPBL, skin57Not givenGVHDNot determined15
qPCRPBL, CSF7478Delayed platelet engraftmentNot determined245
qPCRPBMC20cNot givenRash and fever (2/20)Not determined79
VIPBMC8238RashB447
VIPBMC22Not givenSkin rashNot determined450
VIPBMC2646NoneB197
VIPBMC and/or bone marrow2548Skin rashNot determined456
  • a RT-PCR, reverse transcriptase PCR; qPCR, quantitative (real-time) PCR; VI, virus isolation; IHC, immunohistochemistry.

  • b PBL, peripheral blood lymphocytes; BALF, bronchoalveolar lavage fluid.

  • c Patients in this study were all HCMV seronegative.

  • d GVHD, graft-versus-host disease.